<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="149848">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02101788</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2014-00629</org_study_id>
    <secondary_id>NCI-2014-00629</secondary_id>
    <secondary_id>GOG-0281</secondary_id>
    <secondary_id>GOG-0281</secondary_id>
    <secondary_id>U10CA027469</secondary_id>
    <secondary_id>U10CA180868</secondary_id>
    <nct_id>NCT02101788</nct_id>
  </id_info>
  <brief_title>Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer</brief_title>
  <official_title>A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients With Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase II/III trial studies how well trametinib works and compares it to
      standard treatment with either letrozole, tamoxifen citrate, paclitaxel, pegylated liposomal
      doxorubicin hydrochloride, or topotecan hydrochloride in treating patients with low-grade
      ovarian cancer or peritoneal cavity cancer that has come back, become worse, or spread to
      other parts of the body. Trametinib may stop the growth of tumor cells by blocking some of
      the enzymes needed for cell growth. It is not yet known whether trametinib is more effective
      than standard therapy in treating patients with ovarian or peritoneal cavity cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To estimate the progression-free survival (PFS) hazard ratio of trametinib compared to
      that of &quot;commercially available therapies&quot; consisting of one of five commercially available
      agents in women with recurrent low-grade serous carcinoma of the ovary or peritoneum
      previously treated with platinum-based chemotherapy.

      SECONDARY OBJECTIVES:

      I. To determine the nature, frequency and maximum degree of toxicity as assessed by Common
      Terminology Criteria for Adverse Events (CTCAE) version (v)4 for each treatment arm.

      II. To determine the quality of life, as assessed by the Functional Assessment of Cancer
      Therapy-Ovarian (FACT-O).

      III. To compare trametinib to the control arm with regard to patients' self-reported acute
      (up to post-cycle 6) quality of life as measured by the FACT-O-Trial Outcome Index (TOI).

      IV. To compare trametinib to the control arm with regard to patients' self-reported acute
      (up to post-cycle 6) neurotoxicity as measured by the FACT-Gynecologic Oncology Group
      (GOG)-Neurotoxicity (NTX).

      V. To estimate the objective response rate (RR) of patients in each treatment arm.

      TERTIARY OBJECTIVES:

      I. To estimate the overall survival (OS) of patients in each treatment arm. II. To estimate
      the tumor response rate in patients receiving trametinib after crossover from standard of
      care.

      III. To estimate the PFS in patients receiving trametinib after crossover from standard of
      care.

      IV. To compare trametinib to &quot;endocrine standard therapy&quot; (i.e., letrozole, tamoxifen) with
      regard to patients' self-reported acute quality of life and neurotoxicity, as measured by
      the FACT-O-TOI, and FACT-GOG-NTX, respectively.

      V. To examine deoxyribonucleic acid (DNA) isolated from formalin-fixed, paraffin-embedded
      sections of tissue from primary diagnosis, recurrence, and fine needle aspiration/core
      biopsies with next generation sequencing mutational analyses of genes in the
      mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3 kinase (PI3K)/v-akt
      murine thymoma viral oncogene homolog 1 (AKT)/mammalian target of rapamycin (mTOR) pathways
      and to explore their relationship with tumor response in patients treated with trametinib.
      (Translational research objectives) VI. To examine protein levels of estrogen receptor (ER),
      progesterone receptor (PR), phosphorylated (p)mitogen-activated protein kinase 1 (ERK), and
      dual specificity phosphatase 6 (DUSP6) and explore their relationship with tumor response in
      patients treated with trametinib. (Translational research objectives) VII. To identify
      transcriptional signatures by ribonucleic acid sequencing (RNAseq) that will predict
      mitogen-activated protein kinase kinase (MEK) addiction and sensitivity to trametinib.
      (Translational research objectives) VIII. To conduct studies of specific genes in cell-free
      DNA in plasma of patients and to explore their relationship with tumor response to
      trametinib. (Translational research objectives) IX. To examine the pharmacokinetics of
      trametinib. (Translational research objectives)

      OUTLINE: Patients are randomized to 1 of 2 treatment arms.

      ARM A: Patients receive clinician's choice of either letrozole orally (PO) once daily (QD)
      on days 1-28, tamoxifen citrate PO twice daily (BID) on days 1-28, paclitaxel intravenously
      (IV) over 1 hour on days 1, 8, and 15, pegylated liposomal doxorubicin hydrochloride (PLD)
      IV over 1 hour on day 1, or topotecan hydrochloride IV over 30 minutes on days 1, 8, and 15.
      Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
      Patients developing progressive disease may cross over to Arm B.

      ARM B: Patients receive trametinib PO QD on days 1-28. Courses repeat every 28 days in the
      absence of disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up every 3 months for 2 years,
      every 6 months for 3 years, and then annually for 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Time from study entry to time of progression or death, whichever occurs first, assessed up to 10 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Patients will be grouped by their randomized treatment for intention-to-treat analyses (ITT).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events (AEs) assessed using the National Cancer Institute (NCI) CTCAE version 4</measure>
    <time_frame>Up to 10 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The severity of each AE will be assessed. Patients will be tabulated according to their maximum severity for each organ system or preferred term. Summarized with descriptive statistics for the patients in the safety analysis dataset.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Time from study entry to time of death or date of last contact, assessed up to 10 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Based on a log-rank test. Characterized by treatment group with Kaplan-Meier plots and estimates of the median time until death. The log rank test will be used to compare treatment groups with respect to overall survival.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective tumor response rate (complete response and partial response) using the RECIST 1.1</measure>
    <time_frame>Up to 10 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Compared between the arms using logistic regression via a model incorporating study arm and the factors used in the minimization algorithm. The p-value associated with study arm will be obtained from this model. An 80% confidence interval for the odds ratio will be provided.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life as measured by FACT and FACT-NTX</measure>
    <time_frame>Up to 52 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Examined with a mixed model, adjusting for pretreatment TOI score, age, and treatment option (PLD, weekly topotecan hydrochloride, or weekly paclitaxel). The overall type I error for the two primary quality of life (QoL) hypotheses (1 and 2) will be controlled at alpha=0.10 by using a Bonferroni adjustment: each will be tested at alpha=0.0513. The overall alpha for the QoL hypotheses will be controlled by testing the secondary hypothesis only if one or both of the two primary hypotheses are rejected.  All tests will be two-sided.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Mutations of genetic pathways (translational research)</measure>
    <time_frame>Up to day 1 of course 3</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mutations of genes in the MAPK and PI3K/AKT/mTOR pathways will be analyzed. Done using one-sided tests with alpha=0.05.</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in protein levels (translational research)</measure>
    <time_frame>Baseline to up to day 1 of course 3</time_frame>
    <safety_issue>No</safety_issue>
    <description>Protein levels of ER, PR, pERK, and DUSP6 will be analyzed. Done using one-sided tests with alpha=0.05.</description>
  </other_outcome>
  <other_outcome>
    <measure>Transcriptional signatures by RNAseq in predicting MEK addiction and sensitivity to trametinib (translational research)</measure>
    <time_frame>Up to day 1 of course 3</time_frame>
    <safety_issue>No</safety_issue>
    <description>Done using one-sided tests with alpha=0.05.</description>
  </other_outcome>
  <other_outcome>
    <measure>Proteins in cell-free DNA in plasma (translational research)</measure>
    <time_frame>Up to day 1 of course 3</time_frame>
    <safety_issue>No</safety_issue>
    <description>Done using one-sided tests with alpha=0.05.</description>
  </other_outcome>
  <other_outcome>
    <measure>Presence of KRAS mutations (translational research)</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>The association between KRAS TR endpoints will be explored using Cox proportional hazards models.</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacokinetic parameters of trametinib (translational research)</measure>
    <time_frame>Days 15, 29, and 55</time_frame>
    <safety_issue>No</safety_issue>
    <description>Plasma-time concentration data trametinib will be displayed in tables and/or graphs. Population pharmacokinetic parameters of trametinib and combination therapies such as clearance (CL) and volume of distribution (V) will be determined. In addition, the influence of various covariates (e.g. age, weight, and race) on the pharmacokinetic parameters will be examined.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Ovarian Papillary Serous Carcinoma</condition>
  <condition>Ovarian Serous Cystadenocarcinoma</condition>
  <condition>Recurrent Ovarian Epithelial Cancer</condition>
  <condition>Recurrent Primary Peritoneal Cavity Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A (letrozole, tamoxifen, paclitaxel, PLD, topotecan)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive clinician's choice of either letrozole PO QD on days 1-28, tamoxifen citrate PO BID on days 1-28, paclitaxel IV over 1 hour on days 1, 8, and 15, pegylated liposomal doxorubicin hydrochloride IV over 1 hour on day 1, or topotecan hydrochloride IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients developing progressive disease may cross over to Arm B.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (trametinib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive trametinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>letrozole</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm A (letrozole, tamoxifen, paclitaxel, PLD, topotecan)</arm_group_label>
    <other_name>CGS 20267</other_name>
    <other_name>Femara</other_name>
    <other_name>LTZ</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tamoxifen citrate</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm A (letrozole, tamoxifen, paclitaxel, PLD, topotecan)</arm_group_label>
    <other_name>Nolvadex</other_name>
    <other_name>TAM</other_name>
    <other_name>tamoxifen</other_name>
    <other_name>TMX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A (letrozole, tamoxifen, paclitaxel, PLD, topotecan)</arm_group_label>
    <other_name>Anzatax</other_name>
    <other_name>Asotax</other_name>
    <other_name>TAX</other_name>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pegylated liposomal doxorubicin hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A (letrozole, tamoxifen, paclitaxel, PLD, topotecan)</arm_group_label>
    <other_name>CAELYX</other_name>
    <other_name>Dox-SL</other_name>
    <other_name>DOXIL</other_name>
    <other_name>doxorubicin hydrochloride liposome</other_name>
    <other_name>LipoDox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>topotecan hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A (letrozole, tamoxifen, paclitaxel, PLD, topotecan)</arm_group_label>
    <other_name>hycamptamine</other_name>
    <other_name>Hycamtin</other_name>
    <other_name>SKF S-104864-A</other_name>
    <other_name>TOPO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>trametinib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm B (trametinib)</arm_group_label>
    <other_name>GSK1120212</other_name>
    <other_name>JTP-74057</other_name>
    <other_name>Mekinist</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>quality-of-life assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm A (letrozole, tamoxifen, paclitaxel, PLD, topotecan)</arm_group_label>
    <arm_group_label>Arm B (trametinib)</arm_group_label>
    <other_name>quality of life assessment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm A (letrozole, tamoxifen, paclitaxel, PLD, topotecan)</arm_group_label>
    <arm_group_label>Arm B (trametinib)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm A (letrozole, tamoxifen, paclitaxel, PLD, topotecan)</arm_group_label>
    <arm_group_label>Arm B (trametinib)</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with the following tumors are included in the study:

               -  Patients initially diagnosed with low-grade serous ovarian or peritoneal
                  carcinoma that recur as low-grade serous carcinoma (invasive micropapillary
                  serous carcinoma or invasive grade I serous carcinomas as defined by GOG,
                  Federation of Obstetricians and Gynecologists [FIGO], World Health Organization
                  [WHO] or Silverberg)

               -  Patients initially diagnosed with serous borderline ovarian or peritoneal
                  carcinoma that recur as low-grade serous carcinoma (invasive micropapillary
                  serous carcinoma or invasive grade I serous carcinomas as defined by GOG, FIGO
                  WHO or Silverberg)

          -  Patients must have documented low-grade serous carcinoma; confirmation must occur by
             prospective pathology review prior to study entry; the prospective pathology review
             must be done on tissue from the recurrent carcinoma

          -  All patients must have measurable disease as defined by Response Evaluation Criteria
             in Solid Tumors (RECIST) 1.1; measurable disease is defined as at least one target
             lesion that can be accurately measured in at least one dimension (longest diameter to
             be recorded); each lesion must be &gt; 10 mm when measured by computed tomography (CT),
             magnetic resonance imaging (MRI), or caliper measurement by clinical exam; or &gt;= 20
             mm when measured by chest x-ray; lymph nodes must be &gt;= 15 mm in short axis when
             measured by CT or MRI; all imaging studies must be performed within 28 days prior to
             registration

          -  Prior therapy

               -  Patients must have recurred or progressed following at least one platinum-based
                  chemotherapy regimen

               -  Patients may have received an unlimited number of prior therapy regimens

               -  Patients may not have received all of the five choices in the &quot;standard therapy&quot;
                  arm

          -  An image-guided fine needle aspiration/core biopsy of fresh tissue must be obtained
             prior to randomization and submitted for translational research

          -  Patients of childbearing potential must have a negative pregnancy test, cannot be
             breast-feeding, and must agree to practice an effective means of birth control prior
             to study entry, for the duration of study participation, and for four months after
             dosing with trametinib ceases

          -  Patients must have signed an approved informed consent and authorization permitting
             release of personal health information

          -  Patients must have a GOG performance status of 0 or 1

          -  Able to swallow and retain orally-administered medication and does not have any
             clinically significant gastrointestinal abnormalities that may alter absorption, such
             as malabsorption syndrome or major resection of the stomach or bowels

          -  Patients must have a left ventricular ejection fraction &gt;= lower limit of normal by
             echocardiogram (ECHO) or multigated acquisition scan (MUGA)

          -  Creatinine clearance &gt;= 50 mL/min

          -  Bilirubin =&lt; 1.5 times upper limit of normal

          -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =&lt; 2.5 times
             upper limit of normal

          -  Albumin &gt;= 2.5 g/dL

          -  Prothrombin time (PT) and activated partial thromboplastin time (APTT) =&lt; 1.5 times
             upper limit of normal

          -  Neutrophil count &gt;= 1.2 x 10^9/L

          -  Platelet count &gt;= 100 x 10^9/L

          -  Hemoglobin &gt;= 9.0 g/dL

          -  If letrozole is selected as the control therapy, patients must be postmenopausal,
             either following bilateral oophorectomy or at least 5 years after spontaneous
             menopause; patients within 5 years of spontaneous menopause or who have had a
             hysterectomy without bilateral oophorectomy must have postmenopausal luteinizing
             hormone (LH) and follicle stimulating hormone (FSH) levels; patients on hormone
             replacement therapy (HRT) must agree to withdrawal of hormone therapy before
             letrozole is started

        Exclusion Criteria:

          -  Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for
             nitrosoureas or mitomycin C) prior to entering the study or those who have not
             recovered from adverse events due to agents administered more than 4 weeks earlier

          -  If patients have had a potential index lesion radiated, it must have progressed post
             radiation therapy to be used as a measurable eligibility lesion

          -  Patients may not have received prior MEK, v-Ki-ras2 Kirsten rat sarcoma viral
             oncogene homolog (KRAS), or v-raf murine sarcoma viral oncogene homolog B1 (BRAF)
             inhibitor therapy

          -  Current use of a prohibited medication; the following medications or non-drug
             therapies are prohibited:

               -  Patients may not be receiving any other anti-cancer or investigational agents

               -  The concurrent use of all herbal supplements is prohibited during the study
                  (including, but not limited to St. John's Wort, kava, ephedra [ma huang], gingko
                  biloba, dehydroepiandrosterone [DHEA], yohimbe, saw palmetto, or ginseng)

          -  Patients with known leptomeningeal or brain metastases or spinal cord compression
             should be excluded from this clinical trial

          -  Patients with a bowel obstruction or any other gastrointestinal condition that might
             affect absorption of the oral drug should be excluded; this would include patients
             with inability to swallow and retain orally-administered medication, malabsorption
             syndrome, or those with a major resection of the stomach or bowels

          -  Patients with a history of interstitial lung disease or pneumonitis

          -  Patients with a previous or current malignancy at other sites should be excluded,
             with the exception of:

               -  Curatively treated local tumors such as carcinoma-in-situ of the cervix, basal
                  or squamous cell carcinoma of the skin

               -  Tumors for which no relapse has been observed within 5 years

          -  Patients with active hepatitis B or C; human immunodeficiency virus (HIV) infected
             patients with adequate CD4 counts (&gt; 350 cells/mm3) will be eligible; HIV-positive
             patients on combination antiretroviral therapy are ineligible

          -  Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs
             chemically related to the study drug, or excipients, or to dimethyl sulfoxide (DMSO),
             or to Cremophor EL (polyoxyethylated castor oil); please note, exclusion for
             Cremophor is unnecessary unless paclitaxel is the only agent available and the
             patient randomizes to the conventional therapy option

          -  Patients with a history or evidence of cardiovascular risk, including any of the
             following:

               -  Left ventricular ejection fraction (LVEF) &lt; lower limit of normal (LLN)

               -  Bazett's corrected QT (QTcB) &gt;= 480 msec

               -  History or evidence of current clinically significant uncontrolled arrhythmias

               -  Exception: Subjects with controlled atrial fibrillation for &gt; 30 days prior to
                  randomization are eligible

               -  History of (within 6 months prior to randomization) acute coronary syndromes
                  (including myocardial infarction and unstable angina), coronary angioplasty, or
                  stenting

               -  History or evidence of current &gt;= class II congestive heart failure as defined
                  by New York Heart Association (NYHA)

               -  Treatment refractory hypertension defined as a blood pressure of systolic &gt; 140
                  mmHg and/or diastolic &gt; 90 mmHg which cannot be controlled by anti-hypertensive
                  therapy

               -  Patients with intra-cardiac defibrillators or permanent pacemakers

               -  Known cardiac metastases

          -  Patients with a history or current evidence/risk of retinal vein occlusion (RVO) or
             central serous retinopathy (CSR):

               -  History of RVO or CSR, or predisposing factors to RVO or CSR (e.g., uncontrolled
                  glaucoma or ocular hypertension, uncontrolled hypertension, uncontrolled
                  diabetes mellitus, or history of hyperviscosity or hypercoagulability syndromes)

               -  Visible retinal pathology as assessed by ophthalmic exam that is considered a
                  risk factor for RVO or CSR, such as:

                    -  Evidence of new optic disc cupping

                    -  Intraocular pressure &gt; 21 mm Hg as measured by tonography

                    -  Evidence of new visual field defects

          -  Patients with any psychological, familial, sociological, or geographical condition
             that may potentially hamper compliance with the study protocol and follow-up schedule

          -  Patients who require use of a concomitant medication that can prolong the QT interval
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Gershenson</last_name>
    <role>Principal Investigator</role>
    <affiliation>NRG Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Palo Alto Medical Foundation-Gynecologic Oncology</name>
      <address>
        <city>Mountain View</city>
        <state>California</state>
        <zip>94040</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Albert L. Pisani</last_name>
      <phone>650-934-7000</phone>
    </contact>
    <investigator>
      <last_name>Albert L. Pisani</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northeast Georgia Medical Center</name>
      <address>
        <city>Gainesville</city>
        <state>Georgia</state>
        <zip>30501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Good Samaritan Regional Health Center</name>
      <address>
        <city>Mount Vernon</city>
        <state>Illinois</state>
        <zip>62864</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jay W. Carlson</last_name>
      <phone>800-821-7532</phone>
      <email>sherrijr@iora.org</email>
    </contact>
    <investigator>
      <last_name>Jay W. Carlson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West Michigan Cancer Center</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raymond S. Lord</last_name>
      <phone>269-373-7458</phone>
    </contact>
    <investigator>
      <last_name>Raymond S. Lord</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Central Care Cancer Center-Carrie J Babb Cancer Center</name>
      <address>
        <city>Bolivar</city>
        <state>Missouri</state>
        <zip>65613</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jay W. Carlson</last_name>
      <phone>800-821-7532</phone>
      <email>sherrijr@iora.org</email>
    </contact>
    <investigator>
      <last_name>Jay W. Carlson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CoxHealth Cancer Center</name>
      <address>
        <city>Branson</city>
        <state>Missouri</state>
        <zip>65616</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jay W. Carlson</last_name>
      <phone>800-821-7532</phone>
      <email>sherrijr@iora.org</email>
    </contact>
    <investigator>
      <last_name>Jay W. Carlson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mercy Hospital-Joplin</name>
      <address>
        <city>Joplin</city>
        <state>Missouri</state>
        <zip>64804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jay W. Carlson</last_name>
      <phone>800-821-7532</phone>
      <email>sherrijr@iora.org</email>
    </contact>
    <investigator>
      <last_name>Jay W. Carlson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Freeman Health System</name>
      <address>
        <city>Joplin</city>
        <state>Missouri</state>
        <zip>64804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jay W. Carlson</last_name>
      <phone>800-821-7532</phone>
      <email>sherrijr@iora.org</email>
    </contact>
    <investigator>
      <last_name>Jay W. Carlson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Phelps County Regional Medical Center</name>
      <address>
        <city>Rolla</city>
        <state>Missouri</state>
        <zip>65401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jay W. Carlson</last_name>
      <phone>800-821-7532</phone>
      <email>sherrijr@iora.org</email>
    </contact>
    <investigator>
      <last_name>Jay W. Carlson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint John's Clinic-Rolla-Cancer and Hematology</name>
      <address>
        <city>Rolla</city>
        <state>Missouri</state>
        <zip>65401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jay W. Carlson</last_name>
      <phone>800-821-7532</phone>
      <email>sherrijr@iora.org</email>
    </contact>
    <investigator>
      <last_name>Jay W. Carlson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint John's Mercy Medical Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jay W. Carlson</last_name>
      <phone>800-821-7532</phone>
      <email>sherrijr@iora.org</email>
    </contact>
    <investigator>
      <last_name>Jay W. Carlson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Louis Cancer and Breast Institute-South City</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jay W. Carlson</last_name>
      <phone>800-821-7532</phone>
      <email>sherrijr@iora.org</email>
    </contact>
    <investigator>
      <last_name>Jay W. Carlson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CoxHealth South Hospital</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65807</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jay W. Carlson</last_name>
      <phone>800-821-7532</phone>
      <email>sherrijr@iora.org</email>
    </contact>
    <investigator>
      <last_name>Jay W. Carlson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mercy Hospital Springfield</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jay W. Carlson</last_name>
      <phone>800-821-7532</phone>
      <email>sherrijr@iora.org</email>
    </contact>
    <investigator>
      <last_name>Jay W. Carlson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nebraska Methodist Hospital</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter C. Morris</last_name>
      <phone>402-354-7939</phone>
      <email>kathryn.bartz@nmhs.org</email>
    </contact>
    <investigator>
      <last_name>Peter C. Morris</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donna T. McNamara</last_name>
      <phone>201-996-2879</phone>
    </contact>
    <investigator>
      <last_name>Donna T. McNamara</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Strecker Cancer Center-Belpre</name>
      <address>
        <city>Belpre</city>
        <state>Ohio</state>
        <zip>45714</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John P. Kuebler</last_name>
      <phone>614-566-3275</phone>
    </contact>
    <investigator>
      <last_name>John P. Kuebler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Adena Regional Medical Center</name>
      <address>
        <city>Chillicothe</city>
        <state>Ohio</state>
        <zip>45601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John P. Kuebler</last_name>
      <phone>614-566-3275</phone>
    </contact>
    <investigator>
      <last_name>John P. Kuebler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbus CCOP</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John P. Kuebler</last_name>
      <phone>614-566-3275</phone>
    </contact>
    <investigator>
      <last_name>John P. Kuebler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbus Oncology and Hematology Associates Inc</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John P. Kuebler</last_name>
      <phone>614-566-3275</phone>
    </contact>
    <investigator>
      <last_name>John P. Kuebler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Doctors Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43228</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John P. Kuebler</last_name>
      <phone>614-566-3275</phone>
    </contact>
    <investigator>
      <last_name>John P. Kuebler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Grant Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John P. Kuebler</last_name>
      <phone>614-566-3275</phone>
    </contact>
    <investigator>
      <last_name>John P. Kuebler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Carmel Health Center West</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43222</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John P. Kuebler</last_name>
      <phone>614-566-3275</phone>
    </contact>
    <investigator>
      <last_name>John P. Kuebler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Mark H Zangmeister Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John P. Kuebler</last_name>
      <phone>614-566-3275</phone>
    </contact>
    <investigator>
      <last_name>John P. Kuebler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Riverside Methodist Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John P. Kuebler</last_name>
      <phone>614-566-3275</phone>
    </contact>
    <investigator>
      <last_name>John P. Kuebler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Grady Memorial Hospital</name>
      <address>
        <city>Delaware</city>
        <state>Ohio</state>
        <zip>43015</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John P. Kuebler</last_name>
      <phone>614-566-3275</phone>
    </contact>
    <investigator>
      <last_name>John P. Kuebler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Delaware Health Center-Grady Cancer Center</name>
      <address>
        <city>Delaware</city>
        <state>Ohio</state>
        <zip>43015</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John P. Kuebler</last_name>
      <phone>614-566-3275</phone>
    </contact>
    <investigator>
      <last_name>John P. Kuebler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Delaware Radiation Oncology</name>
      <address>
        <city>Delaware</city>
        <state>Ohio</state>
        <zip>43015</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John P. Kuebler</last_name>
      <phone>614-566-3275</phone>
    </contact>
    <investigator>
      <last_name>John P. Kuebler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lancaster Radiation Oncology</name>
      <address>
        <city>Lancaster</city>
        <state>Ohio</state>
        <zip>43130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John P. Kuebler</last_name>
      <phone>614-566-3275</phone>
    </contact>
    <investigator>
      <last_name>John P. Kuebler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fairfield Medical Center</name>
      <address>
        <city>Lancaster</city>
        <state>Ohio</state>
        <zip>43130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John P. Kuebler</last_name>
      <phone>614-566-3275</phone>
    </contact>
    <investigator>
      <last_name>John P. Kuebler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Marietta Memorial Hospital</name>
      <address>
        <city>Marietta</city>
        <state>Ohio</state>
        <zip>45750</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John P. Kuebler</last_name>
      <phone>614-566-3275</phone>
    </contact>
    <investigator>
      <last_name>John P. Kuebler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Knox Community Hospital</name>
      <address>
        <city>Mount Vernon</city>
        <state>Ohio</state>
        <zip>43050</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John P. Kuebler</last_name>
      <phone>614-566-3275</phone>
    </contact>
    <investigator>
      <last_name>John P. Kuebler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Licking Memorial Hospital</name>
      <address>
        <city>Newark</city>
        <state>Ohio</state>
        <zip>43055</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John P. Kuebler</last_name>
      <phone>614-566-3275</phone>
    </contact>
    <investigator>
      <last_name>John P. Kuebler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Newark Radiation Oncology</name>
      <address>
        <city>Newark</city>
        <state>Ohio</state>
        <zip>43055</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John P. Kuebler</last_name>
      <phone>614-566-3275</phone>
    </contact>
    <investigator>
      <last_name>John P. Kuebler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southern Ohio Medical Center</name>
      <address>
        <city>Portsmouth</city>
        <state>Ohio</state>
        <zip>45662</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John P. Kuebler</last_name>
      <phone>614-566-3275</phone>
    </contact>
    <investigator>
      <last_name>John P. Kuebler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Springfield Regional Medical Center</name>
      <address>
        <city>Springfield</city>
        <state>Ohio</state>
        <zip>45505</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John P. Kuebler</last_name>
      <phone>614-566-3275</phone>
    </contact>
    <investigator>
      <last_name>John P. Kuebler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Ann's Hospital</name>
      <address>
        <city>Westerville</city>
        <state>Ohio</state>
        <zip>43081</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John P. Kuebler</last_name>
      <phone>614-566-3275</phone>
    </contact>
    <investigator>
      <last_name>John P. Kuebler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Genesis HealthCare System</name>
      <address>
        <city>Zanesville</city>
        <state>Ohio</state>
        <zip>43701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John P. Kuebler</last_name>
      <phone>614-566-3275</phone>
    </contact>
    <investigator>
      <last_name>John P. Kuebler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert S. Mannel</last_name>
      <phone>405-271-4272</phone>
      <email>julie-traylor@ouhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Robert S. Mannel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tulsa Cancer Institute</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74146</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert S. Mannel</last_name>
      <phone>405-271-4272</phone>
      <email>julie-traylor@ouhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Robert S. Mannel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Abington Memorial Hospital</name>
      <address>
        <city>Abington</city>
        <state>Pennsylvania</state>
        <zip>19001</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Parviz Hanjani</last_name>
      <phone>215-481-2402</phone>
    </contact>
    <investigator>
      <last_name>Parviz Hanjani</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Women and Infants Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul A. DiSilvestro</last_name>
      <phone>401-274-1122</phone>
    </contact>
    <investigator>
      <last_name>Paul A. DiSilvestro</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alpa M. Nick</last_name>
      <phone>713-792-3245</phone>
    </contact>
    <investigator>
      <last_name>Alpa M. Nick</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>June 2, 2014</lastchanged_date>
  <firstreceived_date>March 28, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Cystadenocarcinoma</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Peritoneal Neoplasms</mesh_term>
    <mesh_term>Cystadenocarcinoma, Serous</mesh_term>
    <mesh_term>Neoplasms, Glandular and Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Tamoxifen</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Topotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
